KANNAPOLIS, NC, USA (November 28, 2023) – Eremid® Genomic Services, LLC(“Eremid”) announces its College of American Pathologists (CAP) accreditation, complementing its November 2022 CLIA certification. This landmark demonstrates Eremid’s commitment to meeting and exceeding regulatory standards, proving its ability to provide quality and precision in clinical genomics. This noteworthy development cements Eremid as a trusted partner for end-to-end clinical genomics support capable of delivering high quality test results.
Eremid’s clinical genomics lab offers the latest in genomics technologies and automation, supporting the development of cutting-edge molecular diagnostics. CAP accreditation and CLIA certification reinforce and validate Eremid’s corporate direction, with physicians, patients, partners, and customers benefiting from the quality assurance inherent in accreditation. With a broad range of sequencing technologies at its disposal, including short-read sequencing by Illumina, and the latest long-read sequencing systems from PacBio and Oxford Nanopore Technologies, Eremid stands ready to advance the research, development, validation, and implementation of clinical genomics testing.
“This is a superb achievement by our team,” says Julian Abery, Eremid’s Chief Business Officer. “Attaining both CAP accreditation and CLIA certification is a testament to Eremid’s dedication to meeting the highest standards in handling and analyzing clinical genomics samples. We are committed to scientific integrity and data quality in all aspects of our work. With CAP accreditation, our customers and partners can rest assured of the efficiency of our processes, accuracy of our results, and adherence to the highest laboratory medicine standards.”
Built on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class solutions designed to drive operational excellence, achieve diagnostic confidence, and ensure the best patient care. CAP inspectors examine laboratory records and quality control procedures, as well as staff qualifications, equipment, facilities, safety program, and overall management. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes.
For more information on Eremid Genomic Services, visit https://eremid.com.
Editor’s notes
Eremid® Genomic Services, LLC
Eremid® Genomic Services is a specialty high-complexity CLIA certified, CAP-accredited genomics contract research organization. The company provides technical expertise in all aspects of genomics, delivering high quality science and data through customized, collaborative projects for both clinical and research clients working in human health, nutrition, and agbiotech. Eremid has invested in world-class scientific staff, and cutting-edge genomic instrumentation and automation to create a unique offering that meets the increasing demands for higher data quality, reliability, and accuracy in genomics research and testing.